Galecto, Inc. Employee Directory
Biotechnology ResearchHovedstaden, Denmark11-50 Employees
Galecto, Inc. is a clinical-stage biotechnology company based in Copenhagen, Denmark, focused on developing novel small molecule therapeutics directed at targets central to fibrosis, inflammation, and cancer. Founded by leading fibrosis researchers and biotech executives, it builds on more than a decade of research into galectin proteins and the LOXL2 enzyme to understand disease pathways. The company operates within the biotechnology research industry, pursuing therapies for conditions where these targets influence disease progression. In November 2025, Galecto completed the acquisition of Damora Therapeutics, signaling a notable expansion of its corporate and scientific footprint. Public information indicates its clinical focus includes oncology and liver diseases.